Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach

AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Published
31 Mar 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$14.70
71.5% undervalued intrinsic discount
24 Jul
US$4.19
Loading
1Y
-61.1%
7D
-14.1%

Author's Valuation

US$14.7

71.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update01 May 25
Fair value Decreased 14%

Key Takeaways

  • Stronger market adoption of DANYELZA and international expansion are expected to drive recurring revenue and broaden the patient base.
  • Advancements in antibody engineering and rare oncology pipeline will support new product launches and profitable long-term growth.
  • Persistent net losses, declining U.S. sales, and early-stage unprofitable ventures heighten revenue risks and potential dilution, while competitive and international uncertainties undermine long-term profitability.

Catalysts

About Y-mAbs Therapeutics
    A commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer.
What are the underlying business or industry changes driving this perspective?
  • Anticipated growth in global demand for precision oncology therapies and increased recognition of DANYELZA (notably its addition to the NCCN guidelines) are likely to drive higher patient adoption and market penetration, directly supporting revenue growth.
  • Expansion of DANYELZA into new high-volume U.S. centers, increased international sales via new named patient programs, and the launch of investigator-sponsored trials are expected to broaden the company’s addressable patient population and support recurring revenue increases.
  • Advancements in Y-mAbs’ antibody engineering platform (e.g., proprietary linker-chelator for radiopharmaceuticals) are poised to improve the efficacy and safety of the pipeline, potentially enabling multiple new product launches and expanding future revenue streams while strengthening long-term margins.
  • Progress in deepening the rare oncology pipeline—including trials in osteosarcoma and relapsed/refractory non-Hodgkin’s lymphoma—as well as near-term radiopharmaceutical R&D updates, increases the probability of future high-value milestones and long-term earnings growth.
  • Inclusion of DANYELZA in major treatment guidelines, combined with government incentives and strong orphan drug protections, should enhance pricing power and reimbursement, positively impacting net margins and free cash flow over time.

Y-mAbs Therapeutics Earnings and Revenue Growth

Y-mAbs Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Y-mAbs Therapeutics's revenue will grow by 8.9% annually over the next 3 years.
  • Analysts are not forecasting that Y-mAbs Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Y-mAbs Therapeutics's profit margin will increase from -31.8% to the average US Biotechs industry of 10.5% in 3 years.
  • If Y-mAbs Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $12.1 million (and earnings per share of $0.26) by about July 2028, up from $-28.2 million today.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 68.9x on those 2028 earnings, up from -7.1x today. This future PE is greater than the current PE for the US Biotechs industry at 16.5x.
  • Analysts expect the number of shares outstanding to grow by 1.6% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.4%, as per the Simply Wall St company report.

Y-mAbs Therapeutics Future Earnings Per Share Growth

Y-mAbs Therapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • The company's primary revenue driver, DANYELZA, experienced a significant 28% year-over-year decline in U.S. sales in Q1 2025 due to competitive pressures, slower new patient enrollment, and changing ordering patterns at key institutions—a trend that, if not reversed, could lead to continued revenue concentration risk and overall declining top-line growth.
  • Y-mAbs continues to report net losses ($5.2 million in Q1 2025), and its ability to self-fund operations is limited to a runway through 2027; persistent net losses and the absence of licensing revenue signal a risk of future equity raises for capital, likely resulting in shareholder dilution and pressure on per-share earnings.
  • The Radiopharmaceutical business unit remains solidly unprofitable and in early clinical development, with working capital primarily sourced from DANYELZA’s cash flows; setbacks or delays in Radiopharma clinical progress or failure to achieve regulatory milestones could further strain margins and impede medium
  • and long-term profitability improvement.
  • Competition in neuroblastoma and other pediatric oncology markets remains intense, including clinical trial enrollment competition and the entry or use of maintenance therapies; this could erode Y-mAbs’ market share, slow adoption, and keep pricing power under pressure—negatively affecting revenue and potentially gross margins.
  • The company’s international revenues (ex-U.S. DANYELZA sales grew substantially in Q1 2025 based on named-patient programs and initial launches) may not be sustainable due to lack of recurring stock-ins, seasonality, and uncertain long-term market penetration, which introduces volatility to earnings and limits reliable free cash flow growth.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of $14.7 for Y-mAbs Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $26.0, and the most bearish reporting a price target of just $3.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $114.6 million, earnings will come to $12.1 million, and it would be trading on a PE ratio of 68.9x, assuming you use a discount rate of 6.4%.
  • Given the current share price of $4.41, the analyst price target of $14.7 is 70.0% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives